sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis

Learn more about:
Related Clinical Trial
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis

Official Title

Macrophages and the Macrophage Activation Markers sCD163 and Mannose Receptor (sMR) in Patients With Wilsons Disease - Associations With Liver Disease Severity and Fibrosis

Brief Summary

      The aim is to investigate macrophage activation markers and correlations to liver fibrosis in
      patients with Wilsons Disease. Researchers wish to investigate associations to neurologic and
      metabolic liver function. Researchers will assess this by comparing blood samples with
      fibrosis and liver function analyses. This study provides new insight into macrophages and
      their involvement in Wilsons Disease.
    



Study Type

Interventional


Primary Outcome

Measurement of the macrophage activation markers sCD163

Secondary Outcome

 Urinary copper excretion in 24 hour urine collection

Condition

Wilsons Disease

Intervention

Fibroscan

Study Arms / Comparison Groups

 Wilsons disease
Description:  All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Procedure

Estimated Enrollment

33

Start Date

February 2016

Completion Date

February 2022

Primary Completion Date

February 2020

Eligibility Criteria

        Inclusion Criteria:

          -  diagnosed with Wilsons disease

        Exclusion Criteria:

        -
      

Gender

All

Ages

18 Years - 100 Years

Accepts Healthy Volunteers

No

Contacts

Henning Grønbæk, Professor, , 

Location Countries

Denmark

Location Countries

Denmark

Administrative Informations


NCT ID

NCT02702765

Organization ID

Wilson sCD163


Responsible Party

Sponsor

Study Sponsor

University of Aarhus

Collaborators

 Aarhus University Hospital

Study Sponsor

Henning Grønbæk, Professor, Principal Investigator, Aarhus University Hospital, Nørrebrogade 44, Aarhus C, Denmark, 8000


Verification Date

September 2019